Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
TRV130A · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| TRV130A | EXPERIMENTAL | - |
| Dextrose in Water | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| TRV130A | DRUG | Intravenous infusion of 1 hour duration |
| Dextrose in Water | DRUG | Intravenous infusion of 1 hour duration |
Inclusion Criteria: * Healthy adult male 19 - 50 years of age * Body weight \>/= 50 kg * Capable of giving written informed consent Exclusion Criteria: * Clinically significant disease or conditions that may place the subject at unacceptable risk as a participant in the study, or that may interfe...
TRV130A is an investigational small molecule developed by Trevena, Inc. It has been studied in a Phase 1 clinical trial involving healthy adult male volunteers. The specific therapeutic indications for TRV130A have not been disclosed, and the compound remains in early-stage clinical development.
TRV130A is being developed by Trevena, Inc., which trades under the ticker symbol TRVN. The company sponsored the Phase 1 clinical study of the compound. Trevena is the developer associated with TRV130A in its clinical program.
TRV130A is in Phase 1 clinical development. One Phase 1 trial has been completed, and no active trials are currently listed. The compound has not been approved by the FDA and remains investigational.
TRV130A has been evaluated in one completed Phase 1 trial, NCT01514578, titled Single Ascending Dose Study of Intravenous TRV130A in Healthy Adult Males. The trial enrolled 74 participants in the United States and was randomized and placebo-controlled, though not double-blind.
The Phase 1 trial NCT01514578 was a single ascending dose study of intravenous TRV130A in healthy adult males. It enrolled 74 participants, was randomized and placebo-controlled, and was conducted in the United States. The study has been completed.